Discovering Novel Therapeutics
Montisera has several novel therapeutic bioactive product at the current development pipeline. The CNS related dependency disorders and major global human suffer causing diseases like Parkinson's disease are included. Also, the company has truly unique, patented plant derived extract. The effect has been proved on lower urinary tract disorders. The origin of the extract is in the Finnish forests, the compound all invented in Montisera.
Description of the montisera pipeline products
Montisera_D4 is a patented hot water extract for prevention and treatment of lower urinary tract diseases. The extract has passed the efficacy tests and is currently at the toxicological tests. The product is directly from Norway spruce, Picea abies.
lower urinary tract symptoms
Lower urinary tract (LUT) diseases cover all diseases which cause lower urinary tract symptoms and includes various functional disorders and diseases of the bladder, prostate and the urethra. Both women and men are affected by LUT symptoms. The most common diseases associated with LUT symptoms related to prostate in men are prostatitis, and benign prostatic hyperplasia (BPH). In women, common diseases related to the bladder are interstitial cystitis/painful bladder syndrome (IC/PBS) and urinary incontinence.
The prevalence of LUTS is known to increase with age. In men, LUTS affect 50% in men aged 51–60 years, increasing to up to 90% in men aged 80 years or older. European and USA studies have reported the major impact of LUTS on quality of life of the patient and their partner. Thus there is an urgent need for new compositions for the prevention and treatment of prostate disorders and LUT associated symptoms without the unwanted side effects.
Naturally occurring compounds for treatment and prevention of LUT symptoms are extensively studied. Plant-derived polysaccharides have been shown to exert biological activities. For example, various hemicelluloses have been proven to exert anti-inflammatory and immunomodulatory properties, such as fractions isolated from Aloe Vera.
Montisera_D15 is a novel, patented molecule for CNS related diseases, especially dependency disorders. The molecule is a novel 6,7-disubstituted-isoquinoline, and both USPTO and EPO have issued patent for its' medical use. Montisera has concluded acute toxicity studies with the compound, and the efficacy studies for the treatment of alcoholism are evident.
substance use disorders
The most common substance of abuse and/or dependence is alcohol. The World Health Organization estimates that about 140 million people throughout the world suffer from alcohol dependence. In the United States and Western Europe, 10 to 20 percent of men and 5 to 10 percent of women at some point in their lives will meet criteria for alcoholism. Most alcoholics develop alcoholism during adolescence or young adulthood.
other therapy areas
The patents cover also the use of molecule in Parkinson's disease, Alzheimer disease, Gaming addiction and Drug addiction.